Notch receptor and effector expression in von Hippel-Lindau disease - Associated central nervous system hemangioblastomas: Laboratory investigation

Journal of Neurosurgery

Volumn 115, Issue 3, 2011, Pages 512-517

  Merrill, Marsha J ^a   Edwards, Nancy A ^a   Lonser, Russell R ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Hemangioblastoma; HES; Notch; Oncology; Vasculature; Von Hippel Lindau disease

Indexed keywords

NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HES 5;

ARTICLE; BLOOD VESSEL REACTIVITY; DISEASE ASSOCIATION; EFFECTOR CELL; HEMANGIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; VON HIPPEL LINDAU DISEASE; WESTERN BLOTTING;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA-BINDING PROTEINS; HEMANGIOBLASTOMA; HOMEODOMAIN PROTEINS; HUMANS; RECEPTORS, NOTCH; TRANSCRIPTION FACTORS; VON HIPPEL-LINDAU DISEASE;

EID: 80052342944     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2011.5.JNS11271     Document Type: Article

References (43)

1. Böhling T., Plate K.H., Haltia M.J., Alitalo K., Neumann H.P.H.: Von Hippel-Lindau disease and capillary haemangioblastoma, in Kleihues P, Cavenee WK (eds): Pathology and Genetics of Tumors of the Nervous System. World Health Organization classification of tumors. Lyon: IARC Press, 2000, pp 223-226
2. Calzada M.J.: Von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clin Transl Oncol 12:160-165, 2010
3. Dikic I., Schmidt M.H.: Notch: Implications of endogenous inhibitors for therapy. Bioessays 32:481-487, 2010
4. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., et al: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038, 2008
5. Gläsker S., Li J., Xia J.B., Okamoto H., Zeng W., Lonser R.R., et al: Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res 66:4167-4172, 2006
6. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., et al: Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9:617-628, 2005 (Pubitemid 41555144)
7. Harper J.A., Yuan J.S., Tan J.B., Visan I., Guidos C.J.: Notch signaling in development and disease. Clin Genet 64:461-472, 2003 (Pubitemid 37493116)
8. Hofmann J.J., Iruela-Arispe M.L.: Notch signaling in blood vessels: Who is talking to whom about what? Circ Res 100:1556-1568, 2007 (Pubitemid 46897259)
9. Karsan A.: The role of notch in modeling and maintaining the vasculature. Can J Physiol Pharmacol 83:14-23, 2005
10. Katoh M., Katoh M.: Integrative genomic analyses on HES/HEY family: Notch-independent HES1, HES3 transcription in undifferentiated ES cells, and Notch-dependent HES1, HES5, HEY1, HEY2, HEYL transcription in fetal tissues, adult tissues, or cancer. Int J Oncol 31:461-466, 2007
11. Konishi J., Kawaguchi K.S., Vo H., Haruki N., Gonzalez A., Carbone D.P., et al: Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67:8051-8057, 2007 (Pubitemid 47395139)
12. Li J.L., Harris A.L.: Crosstalk of VEGF and Notch pathways in tumour angiogenesis: Therapeutic implications. Front Biosci 14:3094-3110, 2009
13. Liu H., Zhang W., Kennard S., Caldwell R.B., Lilly B.: Notch3 is critical for proper angiogenesis and mural cell investment. Circ Res 107:860-870, 2010
14. Liu J., Sato C., Cerletti M., Wagers A.: Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol 92:367-409, 2010
15. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., et al: von Hippel-Lindau disease. Lancet 361:2059-2067, 2003 (Pubitemid 36695052)
16. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999 (Pubitemid 29246458)
17. Mazumdar J., Dondeti V., Simon M.C.: Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 13:4319-4328, 2009
18. Mazur P.K., Einwächter H., Lee M., Sipos B., Nakhai H., Rad R., et al: Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107:13438-13443, 2010
19. Moellering R.E., Cornejo M., Davis T.N., Del Bianco C., Aster J.C., Blacklow S.C., et al: Direct inhibition of the NOTCH transcription factor complex. Nature 462:182-188, 2009
20. Murphy P.A., Lam M.T., Wu X., Kim T.N., Vartanian S.M., Bollen A.W., et al: Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad Sci U S A 105:10901-10906, 2008
21. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., et al: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032-1037, 2006 (Pubitemid 46018516)
22. Ohishi K., Katayama N., Shiku H., Varnum-Finney B., Bernstein I.D.: Notch signalling in hematopoiesis. Semin Cell Dev Biol 14:143-150, 2003 (Pubitemid 36315881)
23. Ohtsuka T., Ishibashi M., Gradwohl G., Nakanishi S., Guillemot F., Kageyama R.: Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J 18:2196-2207, 1999 (Pubitemid 29179176)
24. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al: Targeting Notch to target cancer stem cells. Clin Cancer Res 16:3141-3152, 2010
25. Park D.M., Zhuang Z., Chen L., Szerlip N., Maric I., Li J., et al: von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med 4:e60, 2007
26. Phng L.K., Gerhardt H.: Angiogenesis: A team effort coordinated by notch. Dev Cell 16:196-208, 2009
27. Rae F.K., Stephenson S.A., Nicol D.L., Clements J.A.: Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88:726-732, 2000
28. Ramírez-Bergeron D.L., Runge A., Dahl K.D., Fehling H.J., Keller G., Simon M.C.: Hypoxia affects mesoderm and enhances hemangioblast specification during early development. Development 131:4623-4634, 2004 (Pubitemid 39409701)
29. Renshaw S.: Immunochemical staining techniques, in Renshaw S (ed): Immunohistochemistry. Oxfordshire: Scion, 2007, pp 45-79
30. Roberts A.M., Ohh M.: Beyond the hypoxia-inducible factorcentric tumour suppressor model of von Hippel-Lindau. Curr Opin Oncol 20:83-89, 2008 (Pubitemid 350190986)
31. Sainson R.C., Harris A.L.: Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: From basic research to potential therapies. Angiogenesis 11:41-51, 2008
32. Sang L., Roberts J.M., Coller H.A.: Hijacking HES1: How tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med 16:17-26, 2010
33. Shih IeM, Wang T.L.: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67:1879-1882, 2007
34. Sjölund J., Johansson M., Manna S., Norin C., Pietras A., Beckman S., et al: Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118:217-228, 2008
35. Solecki D.J., Liu X.L., Tomoda T., Fang Y., Hatten M.E.: Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron 31:557-568, 2001 (Pubitemid 32835111)
36. Varnum-Finney B., Purton L.E., Yu M., Brashem-Stein C., Flowers D., Staats S., et al: The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood 91:4084-4091, 1998 (Pubitemid 28261969)
37. Vortmeyer A.O., Frank S., Jeong S.Y., Yuan K., Ikejiri B., Lee Y.S., et al: Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 63:7051-7055, 2003 (Pubitemid 37413438)
38. Westfall S.D., Sachdev S., Das P., Hearne L.B., Hannink M., Roberts R.M., et al: Identification of oxygen-sensitive transcriptional programs in human embryonic stem cells. Stem Cells Dev 17:869-881, 2008
39. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., De Leon G.P., Chen Y., et al: Therapeutic antibody targeting of individual Notch receptors. Nature 464:1052-1057, 2010
40. Xu P., Yu S., Jiang R., Kang C., Wang G., Jiang H., et al: Differential expression of Notch family members in astrocytomas and medulloblastomas. Pathol Oncol Res 15:703-710, 2009
41. Yin L., Velazquez O.C., Liu Z.J.: Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 80: 690-701, 2010
42. Zeuner A., Francescangeli F., Signore M., Venneri M.A., Pedini F., Felli N., et al: The Notch2-Jagged1 interaction mediates stem cell factor signaling in erythropoiesis. Cell Death Differ 18:371-380, 2011
43. ZhuGe Q, Zhong M, Zheng W, Yang GY, Mao X, Xie L, et al: Notch-1 signalling is activated in brain arteriovenous malformations in humans. Brain 132:3231-3241, 2009